Name: Latest research reports of Dr. Lal Pathlabs Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Dr. Lal Pathlabs Ltd.
Rating: 3
Author: ICICI Securities Limited

Dr. Lal Pathlabs Ltd.

NSE: LALPATHLAB | BSE: 539524 | ISIN: INE600L01024 | Industry: Healthcare Services
| Expensive Performer

2721.7000 7.60 (0.28%)

NSE Apr 21, 2025 12:01 PM

25.51% Fall from 52W High

Volume: 40,517

Dr. Lal Pathlabs Ltd.

08 Aug 2024

2721.70

0.28%

Steady quarter; valuation a bit pricey

Hold: Dr. Lal Pathlabs Ltd.

Target

ICICI Securities Limited

Dr Lal PathLabs’ (Dr Lal) Q1FY25 result was in line with our expectations. Growth was driven by better uptick in Swasthfit (up 26.4% YoY) overall sample volume rose 9.3% YoY.

Dr. Lal Pathlabs Ltd. is trading below its 100 day SMA of 2767.6